Xellia Pharms Aps Company Profile
✉ Email this page to a colleague
What is the competitive landscape for XELLIA PHARMS APS, and when can generic versions of XELLIA PHARMS APS drugs launch?
XELLIA PHARMS APS has fourteen approved drugs.
There are eight US patents protecting XELLIA PHARMS APS drugs.
There are fifty patent family members on XELLIA PHARMS APS drugs in thirty countries and twenty-six supplementary protection certificates in nine countries.
Summary for Xellia Pharms Aps
| International Patents: | 50 |
| US Patents: | 8 |
| Tradenames: | 9 |
| Ingredients: | 9 |
| NDAs: | 14 |
Drugs and US Patents for Xellia Pharms Aps
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Xellia Pharms Aps | CASPOFUNGIN ACETATE | caspofungin acetate | POWDER;INTRAVENOUS | 205923-001 | Jul 2, 2018 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Xellia Pharms Aps | DAPTOMYCIN | daptomycin | POWDER;INTRAVENOUS | 206005-001 | Jun 15, 2016 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Xellia Pharms Aps | DAPTOMYCIN | daptomycin | POWDER;INTRAVENOUS | 217415-002 | Jan 30, 2023 | RX | Yes | Yes | 12,053,502 | ⤷ Sign Up | ⤷ Sign Up | ||||
| Xellia Pharms Aps | VANCOMYCIN HYDROCHLORIDE | vancomycin hydrochloride | SOLUTION;INTRAVENOUS | 211962-003 | Feb 15, 2019 | RX | Yes | Yes | 10,849,956 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Xellia Pharms Aps Drugs
Supplementary Protection Certificates for Xellia Pharms Aps Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1115417 | SPC/GB06/024 | United Kingdom | ⤷ Sign Up | SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB06/024 GRANTED TO CUBIST PHARMACEUTICALS, INC IN RESPECT OF THE PRODUCT DAPTOMYCIN, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6162 DATED 27 JUNE 2007 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 22 JANUARY 2021. |
| 0536515 | 300244 | Netherlands | ⤷ Sign Up | PRODUCT: TIGECYCLINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF METAALCOMPLEX, IN HET BIJZONDER TIGECYCLINE; FIRST REGISTRATION, DATE: EU/1/06/336/001, 20060424 |
| 0536515 | 06C0031 | France | ⤷ Sign Up | PRODUCT NAME: TIGECYCLINE; REGISTRATION NO/DATE: EU/01/06/336/001 20060424 |
| 1115417 | SZ 22/2006 | Austria | ⤷ Sign Up | PRODUCT NAME: DAPTOMYCIN |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
